Updated monarchE Trial Data Shows Abemaciclib Continues to Benefit Patients With High-risk, HR-positive, HER2-negative, Early-stage Breast Cancer
SAN ANTONIO – Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK)...